Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Completed · Phase 2

Conditions studied: Congestive Heart Failure

In brief

This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.

Key facts

Study ID

NCT00752596

Run by

Forest Laboratories

People needed

1

Starts

2005-09-01

Expected to finish

2006-07-01

Last updated by the study team

2017-02-01

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• No inclusion criteria as the patient to be included is this compassionate use protocol is currently receiving azimilide therapy

You may not qualify if…

• Currently taking Class I or other Class III antiarrhythmic drug or other drugs that may prolong QT interval.
• Is unwilling or unable to give or understand informed consent.

Where it is running

• Research Site — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.